Document Type : Original articles


Department of Pharmacology and Clinical Pharmacy, College of Pharmacy, University of Duhok, Iraq


Background: Obesity and insulin resistance elevate plasma leptin, while it lowers plasma levels of soluble leptin receptors (sOB-R).
Objectives: To measure the levels of sOB-R in patients with type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) and compare it to healthy controls. The study also aimed to investigate the influence of metformin on the levels of sOB-R in patients with T2DM and MetS.
Materials and Methods: A cross-sectional study was conducted on 66 participants (33 patients and 33 controls). Patients were divided into two groups; Group I included 17 newly diagnosed T2DM patients, and Group II included 16 patients with MetS. Patients were studied before and 3 months after treatment with 850 mg metformin treatment. Group III included 33 non-obese healthy individuals as a control group. Measurements such as height, weight, waist circumference, hip circumference, blood pressure examination, and biochemical tests including fasting blood sugar, HbA1c, total cholesterol (Ch), triglyceride, high-density lipoprotein (HDL), insulin level, plasma sOB-R levels were performed. Ch/HDL ratio, non-HDL cholesterol, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), Waist Hip Ratio (WHR), and Body Mass Index (BMI) were calculated.
Results: No statistically significant difference was found among the groups regarding sOB-R levels initially, but after metformin treatment, T2DM patients showed a significantly higher level (10.19 ng/ml). There was a significant increase in the levels of sOB-R after metformin treatment, as it increased from 7.82 ng/ml to 10.19 ng/ml in T2DM, and from 6.92 ng/ml to 7.82 ng/ml in MetS patients. 
Conclusion: Metformin significantly increases the plasma levels of sOB-R in T2DM patients but only slightly increases these levels in MetS patients.


Main Subjects

[1]      M. Schaab and J. Kratzsch, “The soluble leptin receptor,” Best Pract. Res. Clin. Endocrinol. Metab., vol. 29, no. 5, pp. 661–670, 2015, doi: 10.1016/j.beem.2015.08.002.
[2]      A. B. Olokoba, O. A. Obateru, and L. B. Olokoba, “Type 2 diabetes mellitus: A review of current trends,” Oman Med. J., vol. 27, no. 4, pp. 269–273, 2012, doi: 10.5001/omj.2012.68.
[3]      A. Kohlgruber and L. Lynch, “Adipose Tissue Inflammation in the Pathogenesis of Type 2 Diabetes,” Curr. Diab. Rep., vol. 15, no. 11, pp. 1–11, 2015, doi: 10.1007/s11892-015-0670-x.
[4]      D. Yu et al., “Effects of body fat on the associations of high-molecular-weight adiponectin, leptin and soluble leptin receptor with metabolic syndrome in Chinese,” PLoS One, vol. 6, no. 2, 2011, doi: 10.1371/journal.pone.0016818.
[5]      U. Lausten-Thomsen et al., “Reference values for serum leptin in healthy non-obese children and adolescents,” Scand. J. Clin. Lab. Invest., vol. 76, no. 7, pp. 561–567, 2016, doi: 10.1080/00365513.2016.1210226.
[6]      M. Wasim, “Role of Leptin in Obesity,” J. Obes. Weight Loss Ther., vol. 05, no. 02, 2015, doi: 10.4172/2165-7904.1000258.
[7]      K. Popko, A. Kucharska, and M. Wasik, “Leptins Receptors,” Eur. J. Med. Res., vol. 15, no. 50, pp. 50–54, 2010.
[8]      Q. Sun, R. M. Van Dam, J. B. Meigs, O. H. Franco, C. S. Mantzoros, and F. B. Hu, “Leptin and soluble leptin receptor levels in plasma and risk of type 2 diabetes in U.S. women: A prospective study,” Diabetes, vol. 59, no. 3, pp. 611–618, 2010, doi: 10.2337/db09-1343.
[9]      C. Sommer et al., “Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans,” J. Clin. Endocrinol. Metab., vol. dgac699, pp. 1–10, 2022.
[10]    G. Rena, D. G. Hardie, and E. R. Pearson, “The mechanisms of action of metformin,” Diabetologia, vol. 9, no. 60, pp. 1577–1585, 2017, doi: 10.1007/s00125-017-4342-z.
[11]    Y. Saisho, “Metformin and Inflammation : Its Potential Beyond Glucose-lowering Effect,” Endocrine, Metab. Immune Disord. Targets, vol. 15, no. 3, pp. 196–205, 2015.
[12]    S. K. Malin and S. R. Kashyap, “Effects of metformin on weight loss: potential mechanisms,” Curr. Opin. Endocrinol. Diabetes. Obes., vol. 21, no. 5, pp. 323–329, 2014, doi: 10.1097/MED.0000000000000095.
[13]    I. H. Mahmood and H. A. Tawfiq, “Effects of Metformin vs. Glibenclamide on Serum Leptin Concentration in Type 2 Diabetic Patients,” Rafidain J. Sci., vol. 24, no. 7, pp. 34–41, 2013, doi: 10.33899/rjs.2013.77814.
[14]    D. Care and S. S. Suppl, “Classification and Diagnosis of Diabetes : Standards of Medical Care in Diabetes — 2022,” Diabetes Care, vol. 45, no. Suppl, pp. 17–38, 2022.
[15]    P. L. Huang, “A comprehensive definition for metabolic syndrome,” DMM Dis. Model. Mech., vol. 2, no. 5–6, pp. 231–237, 2009, doi: 10.1242/dmm.001180.
[16]    R. Gandhi, F. Razak, P. Tso, J. R. Davey, and N. N. Mahomed, “Metabolic syndrome and the incidence of symptomatic deep vein thrombosis following total knee arthroplasty,” J. Rheumatol., vol. 36, no. 10, pp. 2298–2301, 2009, doi: 10.3899/jrheum.090282.
[17]    R. Gandhi, H. Dhotar, D. Tsvetkov, and N. N. Mahomed, “The relation between body mass index and waist-hip ratio in knee osteoarthritis,” Can. J. Surg., vol. 53, no. 3, pp. 151–154, 2010.
[18]    T. Morioka et al., “Plasma soluble leptin receptor levels are associated with pancreatic b-cell dysfunction in patients with type 2 diabetes,” J. Diabetes Investig., vol. 9, no. 1, pp. 55–62, 2018, doi:
[19]    T. Ogawa et al., “Relationships between serum soluble leptin receptor level and serum leptin and adiponectin levels, insulin resistance index, lipid profile, and leptin receptor gene polymorphisms in the Japanese population,” Metabolism., vol. 53, no. 7, pp. 879–885, 2004, doi: 10.1016/j.metabol.2004.02.009.
[20]    X. Tang et al., “Metformin increases hepatic leptin receptor and decreases steatosis in mice,” J. Endocrinol., vol. 230, no. 2, pp. 227–237, 2016, doi: 10.1530/JOE-16-0142.